文献速递前列腺癌

将前列腺癌胚系遗传学引入临床实践

Bringing Prostate Cancer Germline Genetics into Clinical Practice.
PubMed 文献 · J Urol · 2019-07-08

本文综述了前列腺癌胚系遗传学改变的临床意义,检索了2001年以来PubMed及相关网站文章。DNA损伤修复基因和错配修复基因突变可驱动前列腺癌发生,遗传咨询联合多面板基因检测有助于识别突变携带者,家系级联检测影响可超出先证者。BRCA1/BRCA2携带者PSA>3 ng/ml时癌症检出率显著升高,BRCA2等突变与侵袭性疾病相关,DNA损伤修复缺陷的转移性去势抵抗性前列腺癌对PARP靶向治疗有积极反应。

要点

  • DNA损伤修复基因和错配修复基因的胚系突变可驱动前列腺癌发生。
  • BRCA1/BRCA2携带者PSA>3 ng/ml时癌症检出率显著升高。
  • DNA损伤修复缺陷的转移性去势抵抗性前列腺癌对PARP靶向治疗有积极反应。

核心结论

  • 新兴证据支持将胚系遗传咨询和检测作为前列腺癌管理的关键组成部分。
  • 需要进一步研究以阐明较少已知胚系突变的临床意义,并开发该患者人群的最佳筛查、早期检测和治疗范式。

研究设计与样本

  • 综述:检索PubMed中2001年以来发表的英文文章,关键词为「germline mutations」「BRCA」「family history」或「prostate cancer genetics」,并使用相关网站数据。

主要发现

  • DNA损伤修复基因(BRCA1、BRCA2、CHEK2、ATM和PALB2)及DNA错配修复基因(MLH1、MSH2、MSH6和PMS2)的多种胚系突变可驱动前列腺癌发展。
  • 来自IMPACT研究(ClinicalTrials.gov NCT00261456)的数据显示,BRCA1和BRCA2携带者在PSA大于3 ng/ml时癌症检出率显著升高。
  • BRCA2及可能其他DNA损伤修复突变与侵袭性疾病相关,但其对局限性疾病管理的影响尚不清楚。
  • 有强证据表明,具有DNA损伤修复缺陷的转移性去势抵抗性前列腺癌患者对靶向PARP酶治疗有积极反应。
  • 在许多癌症中也有证据表明,肿瘤突变负荷增加的患者(如Lynch综合征)对免疫检查点抑制剂特别敏感。

临床怎么用

  • 作者认为,新兴证据支持将胚系遗传咨询和检测作为前列腺癌管理的关键组成部分。
  • 作者指出,仔细的遗传咨询联合多面板基因检测可帮助识别携带这些突变的男性,并增进对疾病风险的理解。
  • 作者指出,家系成员的级联检测可产生远超先证者的影响。
  • 作者指出,对于携带致病性胚系突变的男性,最佳早期检测范式尚未明确。
  • 作者指出,需要进一步研究以阐明较少已知胚系突变的临床意义,并开发最佳筛查、早期检测和治疗范式。

局限性

  • 原文指出,对于携带致病性胚系突变的男性,最佳早期检测范式尚未明确。
  • 原文指出,BRCA2及可能其他DNA损伤修复突变对局限性疾病管理的影响尚不清楚。
  • 原文结论指出,需要进一步研究以阐明较少已知胚系突变的临床意义,并开发最佳筛查、早期检测和治疗范式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Until recently the role of germline genetics in prostate cancer care was not well defined. While important questions remain, we reviewed the current understanding of germline genetic alterations related to prostate cancer. We discuss the clinical implications for genetic counseling, genetic testing, early detection and treatment in men with these mutations. MATERIALS AND METHODS: We searched PubMed® for English language articles published since 2001 with the key words "germline mutations," "BRCA," "family history" or "prostate cancer genetics." We also used relevant data from websites, including the Centers for Medicare and Medicaid Services, National Comprehensive Cancer Network®, Bureau of Labor Statistics and National Society of Genetic Counselors websites. RESULTS: A number of germline mutations in DNA damage repair genes ( BRCA1, BRCA2, CHEK2, ATM and PALB2) and in DNA mismatch repair genes ( MLH1, MSH2, MSH6 and PMS2) can drive the development of prostate cancer. Careful genetic counseling coupled with multipanel gene testing can help identify men with these mutations and provide enhanced understanding of the disease risk. Cascade testing of family members can then have an impact extending well beyond the index patient. In men with a pathogenic germline mutation the optimal early detection paradigm is not well defined. Data from the IMPACT study ( ClinicalTrials.gov NCT00261456) that the cancer detection rate is substantially elevated in BRCA1 and BRCA2 carriers at prostate specific antigen greater than 3 ng/ml has helped establish the importance of close prostate specific antigen screening in these men. Additionally, BRCA2 and likely other DNA damage repair mutations are associated with aggressive disease, although it is not yet clear how this impacts localized disease management. However, there is strong evidence that patients with metastatic, castration resistant prostate cancer who have DNA damage repair defects respond positively to targeting PARP enzymes. In many cancers there is also evidence that patients with an increased tumor mutational burden, such as in Lynch syndrome, are particularly sensitive to immune checkpoint inhibitors. CONCLUSIONS: Emerging evidence supports the implementation of germline genetic counseling and testing as a key component of prostate cancer management. Further research is needed to elucidate the clinical significance of lesser known germline mutations and develop optimal screening, early detection and treatment paradigms in this patient population.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Das S, Salami SS, Spratt DE, et al. Bringing Prostate Cancer Germline Genetics into Clinical Practice. J Urol. 2019. PMID: 30730411. doi:10.1097/JU.0000000000000137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。